|
Table of Contents 1. Analyst View
2. Research Methodology
3. Orphan Drug – An Introduction
4. Drivers and Challenges
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Increasing Prevalence of Chronic Diseases
4.1.3 Shorter Development Timeline & Orphan Drug Exclusivity (ODE)
4.1.4 Grants and Tax Credits
4.2 Challenges
4.2.1 High Cost of Orphan Drugs
4.2.2 Lack of Disease History Awareness & Research Participants
4.2.3 Increased Competition from Generics Industry
5. Global Orphan Drug Market - Overview
6. Market Segmentation
6.1 By Type
6.2 By Geography
6.3 By Applications
7. Current Status of Orphan Drugs in Pipeline
8. Trends and Developments
8.1 Rise in Number of Orphan Drugs for Oncology
8.2 Gene Therapy- Gaining Popularity for Rare Conditions
9. Mergers and Acquisitions
10. Regulatory Scenario
10.1 US
10.2 EU
10.3 Japan
10.4 India
10.5 China
11. Competitive Landscape
12. Key Player Analysis
12.1 Novartis
12.2 F. Hoffmann-La Roche AG
12.3 Celgene Corporation
12.4 Pfizer Inc.
12.5 Sanofi
12.6 Bristol-Myers Squibb
12.7 Johnson & Johnson
12.8 Merck & Co., Inc.
12.9 Boehringer Ingelheim GmbH
12.10 AbbVie
13. Opportunities & Recommendations
13.1 Opportunities
13.2 Recommendations List of Figures: Figure 5-1: Global - Orphan Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Orphan Drugs Market by Type (%), 2014
Figure 6-2: Global - Orphan Drugs Market by Geography (%), 2014
Figure 6-3: Global - Orphan Drugs Market by Applications (%), 2014
Figure 11-1: Share of Major Players in Orphan Drugs Market (%), 2014
Figure 12-1: Novartis - Breakup of Revenue by Geographies (%), 2014
Figure 12-2: Roche - Breakup of Revenue by Geographies (%), 2014
Figure 12-3: Celgene Corporation - Breakup of Revenue by Geographies (%), 2014
Figure 12-4: Pfizer Inc - Breakup of Revenue by Geographies (%), 2014
Figure 12-5: Sanofi – Breakup of Revenue by Geographies (%), 2014
Figure 12-6: Bristol Myers Squibb – Breakup of Revenue by Geographies (%), 2014
Figure 12-7: Johnson & Johnson - Breakup of Revenue by Geographies (%), 2014
Figure 12-8: Merck & Co., Inc. - Breakup of Revenue by Geographies (%), 2014
Figure 12-9: Boehringer Ingelheim GmbH - Break up of Revenue by Geographies (%), 2014
Figure 12-10: AbbVie - Break up of Revenue by Geographies (%), 2014 List of Tables: Table 7-1: Major Orphan Drugs Pipeline
Table 9-1: Major Consolidations in Orphan Drug Market (2014-2015)
Table 11-1: Global - Major Orphan Drugs Revenue (Billion US$), 2014
Table 12-1: Novartis - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-2: Novartis - Orphan Drugs
Table 12-3: Roche - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-4: Roche - Orphan Drugs
Table 12-5: Celgene Corporation - Orphan Drugs
Table 12-6: Pfizer Inc - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-7: Pfizer Inc - Orphan Drugs
Table 12-8: Sanofi - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-9: Sanofi - Orphan Drugs
Table 12-10: Bristol Myers Squibb - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-11: Bristol Myers Squibb - Orphan Drugs
Table 12-12: Johnson & Johnson - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-13: Johnson & Johnson - Orphan Drugs
Table 12-14: Merck & Co., Inc. - Revenue by Business Segments (Billion US$), 2013 & 2014
Table 12-15: Merck & Co., Inc. - Orphan Drugs
Table 12-16: Boehringer Ingelheim GmbH - Revenues by Business Segment (Billion US$), 2013 & 2014
Table 12-17: Boehringer Ingelheim GmbH - Orphan Drugs
Table 12-18: AbbVie - Orphan Drugs
|
현재위치 : 
